CD169+ TAMs exhibit dual roles in cancer progression, correlating with improved prognosis in glioblastomas, HCC, and gastric cancers through immune activation, while promoting aggression in breast, endometrial, and bladder cancers via immunosuppressive mechanisms. Here, SIGLEC1 is linked to cancer.